The second China-UK Health Innovation Dialogue in London, England, on Monday brought together government officials, regulators, business leaders, and academics from both countries to explore opportunities for closer cooperation in healthcare.
The event is part of London Life Sciences Week, an annual citywide offering that was expected to draw more than 5,000 attendees.
Co-hosted by the China Investment Promotion Agency under the Ministry of Commerce and the UK's Department for Business, Innovation, Science and Trade, the event was held under the China-UK Health Innovation Platform, an initiative agreed to at the 11th China-UK Economic and Financial Dialogue.
The platform aims "to establish a long-term, efficient and practical mechanism, guided by governments and driven by the market, for bilateral healthcare cooperation", said Tang Song, deputy director of the China Investment Promotion Agency.
The inaugural health dialogue took place in Beijing in 2025. Working groups on mental health and the silver economy have since been established.
At the 25th China International Fair for Investment and Trade in Xiamen, where the UK was the guest country of honor, the platform also supported matchmaking events and high-level dialogues, with major deals in healthcare reached.
Appetite for two-way exchanges is accelerating, particularly as China is rising as a global powerhouse in health innovation, industry insiders told China Daily at the event.
"China's most striking progress in healthcare in recent years has been the speed at which research is translated into clinical applications and commercial products," said Wen Tianyu, director of business development at China's Thalys Medical Technology Group. "Advances in materials, precision manufacturing, and supply chain management have significantly shortened the journey from laboratory prototype to mass production. China's large patient population and diverse disease profiles also provide a wealth of real-world data to develop, apply, and refine new tools."
And UK innovators stand to benefit from those advantages, Wen said.
"Moreover, Chinese companies are increasingly developing innovative drugs at home and bringing them to international markets through out-licensing deals. To me, this marks a real shift from growth in volume to advances in quality," Wen noted.
A study published in August that was co-authored by researchers from Wuhan University, Peking University, and King's College London found China had more than 7,000 active drug development projects by early 2025, accounting for about 29.5 percent of the global pipeline and ranking second only to the United States.
While earlier approvals of China-developed drugs were dominated by generic medicines and products in more established therapeutic areas, recent years have seen a rapid increase in innovative medicines, including small-molecule drugs and biologics entering major international markets, which signals China's growing contribution to the global pharmaceutical industry, the study also reported.
Riding that wave, UK healthcare businesses are increasingly viewing China as a source of innovation.
For example, AstraZeneca, announced in January a $15-billion investment in China through 2030, which spans the value chain from drug discovery and clinical development to manufacturing. GSK last year struck a $500-million deal with China's Jiangsu Hengrui Pharmaceuticals to develop up to a dozen new medicines.
Chinese healthcare players at the same time are also seeking to expand their international reach, something that is reshaping their approach to product development.
For Zhi Yuan, chairman of Baoyu Mingzhi Medical Device Service Group, this means factoring in regulatory requirements from major markets – such as China, the European Union, and the US – from the initial design stage, paving the way for more efficient entry across different markets.
"In just 20 years, China has moved from heavy reliance on imported medical equipment to widespread use of homemade products across almost every category, covering some 14,000 types of devices," he said. "The world is definitely more aware of this rapid transformation. For Chinese companies, the question now is how best to truly go global."
Both Wen and Zhi recognized the key role of government-initiated platforms in facilitating dialogue between businesses on both sides.
"Momentum in bilateral relations and the implementation of favorable policies have made it easier for engagement," said Wen. "This year, the discussions we had are much more practical: these are the steps you need to take to enter the UK market, and these are the regulatory requirements you need to meet. The focus has shifted from simply showcasing capabilities to discussing compliance, making the path into each other's healthcare systems clearer and easier to navigate."
zhengwanyin@mail.chinadailyuk.com
